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We	are	pleased	about	the	general	agreement	that	PBI	does	not	increase	breast	cancer	mortality	in	
comparison	with	WBI	and	it	is	therefore	a	safe	treatment	option	for	suitable	patients.	PBI	with	TARGIT-
IORT	within	a	risk-adapted	approach	has	the	convenience	of	being	completed	at	the	time	of	lumpectomy,	
has	lower	acute	and	late	toxicity1-3,		is	preferred	by	patients4	5,	improves	cosmesis	and	quality	of	life6	7,	is	
less	expensive8	9,		and	reduces	environmental	and	social	costs10.	Common	sense	would	dictate	that	it	
should	become	an	accepted	treatment	option	for	suitable	patients	world-wide.			
	
As	stated	in	our	paper,	we	included	only	published	randomised	trials	that	compared	PBI	vs	WBI	and	
reported	5-year	mortality	data.	Amongst	all	search	results,	every	trial	that	fulfilled	these	criteria	was	
included.	The	number	of	deaths	and	‘proportion	of	patients	with	mortality	events’	were	all	at	a	median	
follow	up	5-6	years.	
	
We	chose	to	emphasise	the	absolute	difference	(and	95%	CI)	rather	than	hazard	ratio,	as	this	gives	the	
exact	rather	than	the	relative	value,	and	is	the	most	relevant	clinical	statistic.	To	put	it	in	perspective,	we	
have	also	mentioned	how	the	difference	is	a	large	proportion	of	the	total	mortality:	a	25%	reduction	in	
mortality	with	PBI.			
	
With	a	large	number	of	randomised	patients	(n=4251),	and	a	low	overall	mortality	(n=207),	the	observed	
difference	between	PBI	and	WBI	was	1.3%,	favouring	PBI.	The	p-values	tell	us	that	if	in	reality	the	
difference	were	zero	and	PBI	and	WBI	led	to	identical	mortality,	then	the	probability	of	observing	a	
difference	of	1.3%	favouring	PBI,	is	p=.05	by	the	random	effects	model;	the	corresponding	probability	
using	the	fixed	effects	model	is	p=.13.	Given	that	both	the	probabilities	are	low	and	taking	into	
consideration	that	both	models	found	a	definite	reduction	in	non-breast-cancer	mortality	with	PBI,	but	no	
difference	in	breast-cancer	mortality,	it	is	clear	that	there	is	really	no	meaningful	discrepancy	between	
the	results	of	the	two	models,	and	both	support	the	conclusions.		
	
Higgins	I2	values	for	heterogeneity	were	15.2%,	6.6%	and	9.4%	for	non-breast-cancer,	breast-cancer	and	
total	mortality.	These	low	I2	values	demonstrate	a	low	level	of	variation	across	the	studies	due	to	
potential	heterogeneity	and	also	counter	the	final	point	by	showing	that	the	results	are	not	‘largely	driven	
by	the	TARGIT-A	results’.	 
 
This	meta-analysis	confirms	that	mortality	benefit	we	first	reported	in	the	TARGIT-A	trial11	is	consistent	
across	other	trials	of	PBI.	The	correspondents	ask	why	this	small	difference,	detectable	in	modern	trials,	
was	not	seen	before.	As	previously	suggested12,	in	older	trials	over	50%	patients	died	from	breast	cancer	
in	the	first	5	years13	and	a	1-2%	difference	wouldn’t	be	detectable	until	breast-cancer	mortality	reduced	in	
the	later	years.	On	the	other	hand,	in	these	modern	trials,	<5%	patients	die	–	more	than	half	of	these	
from	causes	other	than	breast	cancer.	So	a	1.3%	difference	is	not	only	statistically	detectable,	but	given	
the	large	number	of	breast	cancers	being	treated,	it	is	clinically	important	enough	for	us	to	consider	a	
change	of	practice.		
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